LLY— Eli Lilly and Company
NYSEHealthcare · Drug Manufacturers - General
Eli Lilly and Company (LLY) stock trades at $1107.08, up 0.45% on the day. With a market capitalization of $987.23 billion, LLY is a mega-cap healthcare stock. It trades at a price-to-earnings (P/E) ratio of 39.4, a forward P/E of 24.9 and earnings per share (EPS) of $28.12. Over the most recent period the company reported 56% year-over-year revenue growth and a net profit margin of 35.0%. Below you'll find LLY's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.
Price & Performance
Performance
Analysis & Verdict
Eli Lilly and Company (LLY) Stock Analysis 2026
Rule-based · Updated daily · Not financial advice
Eli Lilly and Company (LLY) operates in the Drug Manufacturers - General space within the Healthcare sector. With a market cap of $987.2B, it qualifies as a large-cap company. The company is growing revenue strongly while maintaining healthy profitability — a combination that investors typically reward with a premium valuation.
- Forward P/E (24.9×) is lower than trailing P/E (39.4×) — analysts expect earnings to improve
- Revenue grew 56% year-over-year — exceptional top-line expansion
- Earnings grew 170% YoY — bottom-line is expanding fast
- Exceptional profit margin of 35.0% — the business retains a large share of each dollar earned
- ROE of 107.5% shows management efficiently converts equity into profit
- Low beta of 0.52 — less volatile than the market, suitable for conservative portfolios
- P/E of 39.4× is above average — valuation requires continued strong growth to justify
- High debt-to-equity of 139.01× increases financial risk, especially with elevated interest rates
- Price is near its 52-week high — limited near-term upside, higher pullback risk
Verdict
Strong Buy
Multiple fundamental strengths with few red flags. Long-term buyers may find this compelling.
AI Insight
Powered by ClaudeAI-generated analysis for informational purposes only. Not financial advice.
Fair Value Estimates
Current price: $1107.08
Graham Number
√(22.5 × EPS × Book Value)
$148.63
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$76.80
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
9/10
90% score
Pays dividends
15Y hist.15+ years of dividend history
Dividend consistency (5Y+)
15 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
107.5%Return on equity — measures how efficiently capital is used
Positive profit margin
35.0%Net profit margin must be positive — company earns more than it spends
Revenue growth (annual)
+55.5%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
+169.9%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
139.01×Low financial leverage reduces risk of distress
Current ratio above 1
1.50×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$3.5B/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
0.63%Stock must distribute income to shareholders
Financials
Revenue & Results
Key Statistics
Earnings
Next Earnings
Aug 5, 2026
42
days
EPS (TTM)
$28.12
P/E (TTM)
39.4
Fwd P/E
24.9
SEC Filings & Reported Financials
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Insider Transactions
SEC Form 4 · officers, directors & 10% owners
Dividends & Income
Dividends
Current DY
0.63%
5Y Avg Annual
$4.6200
Last Payment
$1.7300
Ex-Date
05/15/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest05/15/2026 | 05/29/2026 | $1.7300 | 0.63% |
02/13/2026 | 02/27/2026 | $1.7300 | 0.63% |
11/14/2025 | 11/28/2025 | $1.5000 | 0.54% |
08/15/2025 | 08/29/2025 | $1.5000 | 0.54% |
05/16/2025 | 05/30/2025 | $1.5000 | 0.54% |
02/14/2025 | 02/28/2025 | $1.5000 | 0.54% |
11/15/2024 | 11/29/2024 | $1.3000 | 0.47% |
08/15/2024 | 08/29/2024 | $1.3000 | 0.47% |
Magic Number
Shares needed to self-fund your next purchase
$1,107.08
Price
$1.7300
Last div. (quarterly)
640
shares
Own 640 LLY shares ($708,531.20) and each quarterly dividend pays for 1 new share — the snowball runs on its own.
Investment target
$708,531.20
New shares / year
+4 shares
Tools & Simulators
If You Had Invested…
Hypothetical return based on historical prices
* Dividend reinvestment calculated at ex-date price. For informational purposes only.
Discover
Related Assets
Healthcare
Related Articles
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; and strategic collaboration with Ascidian Therapeutics for discovery and development of therapies for undisclosed monogenic kidney diseases. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Sector
Healthcare
Industry
Drug Manufacturers - General
Location
Indianapolis, United States
Employees
50,000
LLY — Frequently Asked Questions
Is Eli Lilly and Company (LLY) a good stock to buy in 2026?
Eli Lilly and Company (LLY) shows strengths such as revenue growth of 56%, a strong 35% net margin and a 107% return on equity, while risks include high leverage (debt/equity of 139.0). Whether LLY is a good buy in 2026 depends on your time horizon and risk tolerance — review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.
What is LLY's stock price today?
Eli Lilly and Company (LLY) trades at $1107.08, up 0.45% on the session. Prices on this page update throughout the trading day.
Does LLY pay a dividend?
Yes. Eli Lilly and Company pays an annual dividend of $6.92 per share, a dividend yield of 0.63%. The most recent ex-dividend date was August 14, 2026. Its payout ratio is about 22% of earnings.
Is LLY overvalued?
With a P/E ratio of 39.4×, LLY is valued above the broad-market average for the healthcare sector. Its PEG ratio is 1.48. See the Fair Value Estimates section above for Graham Number and dividend-based price targets.
What is LLY's market cap?
Eli Lilly and Company (LLY) has a market capitalization of $987.23 billion, classifying it as a mega-cap stock in the Healthcare sector.
Disclaimer: This page — including any buy/hold/avoid view, fair value or price estimate — is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.